Literature DB >> 30139408

Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression.

Suzanne van Bronswijk1, Neha Moopen2, Lian Beijers3, Henricus G Ruhe4, Frenk Peeters1.   

Abstract

Despite substantial advances in treatment and management strategies for major depression, less than 50% of patients respond to first-line antidepressant treatment or psychotherapy. Given the growing number of controlled studies of psychotherapy for treatment-resistant depression (TRD) and the preference for psychotherapy of depressed subjects as a treatment option, we conducted a meta-analysis and meta-regression analysis to investigate the effectiveness of psychotherapy for TRD. Seven different psychotherapies were studied in 21 trials that included a total of 25 comparisons. In three comparisons of psychotherapy v. treatment as usual (TAU) we found no evidence to conclude that there is a significant benefit of psychotherapy as compared with TAU. In 22 comparisons of add-on psychotherapy plus TAU v. TAU only, we found a moderate general effect size of 0.42 (95% CI 0.29-0.54) in favor of psychotherapy plus TAU. The meta-regression provided evidence for a positive association between baseline severity as well as group v. individual therapy format with the treatment effect. There was no evidence for publication bias. Most frequent investigated treatments were cognitive behavior therapy, interpersonal psychotherapy, mindfulness-based cognitive therapy, and cognitive behavioral analysis system of psychotherapy. Our meta-analysis provides evidence that, in addition to pharmacological and neurostimulatory treatments, the inclusion of add-on of psychotherapy to TAU in guidelines for the treatment of TRD is justified and will provide better outcomes for this difficult-to-treat population.

Entities:  

Keywords:  Meta-analysis; meta-regression; psychotherapy; treatment resistant depression

Mesh:

Year:  2018        PMID: 30139408     DOI: 10.1017/S003329171800199X

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  16 in total

1.  Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder.

Authors:  Amanda B Namchuk; Irwin Lucki; Caroline A Browne
Journal:  Adv Drug Alcohol Res       Date:  2022-02-21

2.  3,3'-Diindolylmethane and 1,4-dihydroxy-2-naphthoic acid prevent chronic mild stress induced depressive-like behaviors in female mice.

Authors:  Caitlin A Madison; Jacob Kuempel; Georgia Lee Albrecht; Lauren Hillbrick; Arul Jayaraman; Stephen Safe; Robert S Chapkin; Shoshana Eitan
Journal:  J Affect Disord       Date:  2022-04-21       Impact factor: 6.533

Review 3.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

4.  Psychotherapy for Depression Across Different Age Groups: A Systematic Review and Meta-analysis.

Authors:  Pim Cuijpers; Eirini Karyotaki; Dikla Eckshtain; Mei Yi Ng; Katherine A Corteselli; Hisashi Noma; Soledad Quero; John R Weisz
Journal:  JAMA Psychiatry       Date:  2020-07-01       Impact factor: 21.596

5.  The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice.

Authors:  Moriah L Jacobson; Hildegard A Wulf; Caroline A Browne; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2020-09-07       Impact factor: 4.530

Review 6.  Well-being Therapy in Depressive Disorders.

Authors:  Giovanni Mansueto; Fiammetta Cosci
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life: Findings From the EMBARC and STRIDE Studies and the VitalSign6 Project.

Authors:  Manish K Jha; Alan Schatzberg; Abu Minhajuddin; Cherise Chin Fatt; Taryn L Mayes; Madhukar H Trivedi
Journal:  J Clin Psychiatry       Date:  2021-04-13       Impact factor: 5.906

8.  Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental.

Authors:  D Bennabi; T Charpeaud; A Yrondi; J-B Genty; S Destouches; S Lancrenon; N Alaïli; F Bellivier; T Bougerol; V Camus; J-M Dorey; O Doumy; F Haesebaert; J Holtzmann; C Lançon; M Lefebvre; F Moliere; I Nieto; C Rabu; R Richieri; L Schmitt; F Stephan; G Vaiva; M Walter; M Leboyer; W El-Hage; P-M Llorca; P Courtet; B Aouizerate; E Haffen
Journal:  BMC Psychiatry       Date:  2019-08-28       Impact factor: 3.630

Review 9.  Management of Treatment-Resistant Depression: Challenges and Strategies.

Authors:  Daphne Voineskos; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Neuropsychiatr Dis Treat       Date:  2020-01-21       Impact factor: 2.570

10.  Key considerations in the pharmacological management of treatment-resistant depression.

Authors:  Mani Yavi; Ioline D Henter; Lawrence T Park; Carlos Zarate
Journal:  Expert Opin Pharmacother       Date:  2021-07-21       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.